Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

7.1K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Therapies02:49

Cancer Therapies

10.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
Cancer Vaccines01:30

Cancer Vaccines

1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Subviral Agents01:29

Subviral Agents

667
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
667

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanistic model for HEK293 viral vector processes and its application in a digital shadow framework.

Bioprocess and biosystems engineering·2026
Same author

Multi-parameter process optimization for high yield AAV2 vector production using scale-down multi-parallel bioreactor systems and high-throughput analytical tools.

Journal of biotechnology·2025
Same author

Viable cell sorting by fluidized bed centrifugation enables novel cultivation strategies.

Frontiers in bioengineering and biotechnology·2025
Same author

Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.

Cell death and differentiation·2025
Same author

Oncolytic viruses expressing MATEs facilitate target-independent T-cell activation in tumors.

EMBO molecular medicine·2025
Same author

Triple Space-Time Yield in Discontinuous Antibody Biomanufacturing by Combination of Synergetic Process Intensification Strategies.

Bioengineering (Basel, Switzerland)·2023

Related Experiment Video

Updated: Feb 26, 2026

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

9.9K

Oncolytic viruses: adenoviruses.

Julia Niemann1, Florian Kühnel2

  • 1Clinic for Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Carl Neuberg Str. 1, 30625, Hannover, Germany.

Virus Genes
|July 14, 2017
PubMed
Summary

Oncolytic viruses offer potent cancer therapy by directly destroying tumors and stimulating immune responses. Research focuses on enhancing their tumor selectivity and integrating them into broader cancer immunotherapies for improved outcomes.

Keywords:
AdenovirusArmingCheckpoint inhibitionConditional replicationOncolytic virusRetargeting

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K
Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
08:14

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

9.0K

Related Experiment Videos

Last Updated: Feb 26, 2026

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

9.9K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K
Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
08:14

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

9.0K

Area of Science:

  • Oncology
  • Virology
  • Immunotherapy

Background:

  • Oncolytic viruses are engineered to selectively replicate within tumor cells, leading to cancer cell lysis.
  • Beyond direct tumor cell killing, these viruses also activate innate and adaptive immune responses against cancer.
  • Clinical trials, particularly for advanced melanoma, have shown promising long-term tumor remissions attributed to oncolytic virotherapy.

Purpose of the Study:

  • To review the fundamental mechanisms of oncolytic virus action.
  • To outline the current clinical development status of oncolytic virotherapy.
  • To discuss strategies for enhancing tumor selectivity and immune stimulation.

Main Methods:

  • Focus on oncolytic adenoviruses as a model system.
  • Exploration of conditional replication strategies to limit viral activity to tumor tissue.
  • Investigation of targeted delivery methods for improved safety and efficacy.
  • Discussion of methods to optimize virus-induced immunostimulation.

Main Results:

  • Oncolytic viruses demonstrate dual mechanisms of action: direct tumor lysis and immune system activation.
  • Conditional replication and targeted delivery are key strategies to enhance tumor selectivity.
  • Optimizing immunostimulation is crucial for maximizing therapeutic benefits.
  • Oncolytic virotherapy holds potential as a component of integrated cancer treatment strategies.

Conclusions:

  • Oncolytic viruses are versatile therapeutic agents with significant potential in cancer treatment.
  • Enhancing tumor selectivity and immune response modulation are critical for optimizing oncolytic virotherapy.
  • The integration of oncolytic viruses into systemic immunotherapies represents a promising future direction.